152 related articles for article (PubMed ID: 22268628)
1. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.
Yamazaki H; Suemizu H; Shimizu M; Igaya S; Shibata N; Nakamura M; Chowdhury G; Guengerich FP
Chem Res Toxicol; 2012 Feb; 25(2):274-6. PubMed ID: 22268628
[TBL] [Abstract][Full Text] [Related]
2. Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice.
Nishiyama S; Suemizu H; Shibata N; Guengerich FP; Yamazaki H
Chem Res Toxicol; 2015 Nov; 28(11):2088-90. PubMed ID: 26492539
[TBL] [Abstract][Full Text] [Related]
3. In vivo formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice.
Yamazaki H; Suemizu H; Igaya S; Shimizu M; Shibata N; Nakamura M; Chowdhury G; Guengerich FP
Chem Res Toxicol; 2011 Mar; 24(3):287-9. PubMed ID: 21299192
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of primary oxidative metabolites of thalidomide in rats and in chimeric mice humanized with different human hepatocytes.
Miura T; Uehara S; Shimizu M; Suemizu H; Yamazaki H
J Toxicol Sci; 2021; 46(7):311-317. PubMed ID: 34193768
[TBL] [Abstract][Full Text] [Related]
5. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate.
Chowdhury G; Murayama N; Okada Y; Uno Y; Shimizu M; Shibata N; Guengerich FP; Yamazaki H
Chem Res Toxicol; 2010 Jun; 23(6):1018-24. PubMed ID: 20443640
[TBL] [Abstract][Full Text] [Related]
6.
Uehara S; Murayama N; Higuchi Y; Shimizu M; Suemizu H; Guengerich FP; Yamazaki H
Chem Res Toxicol; 2024 May; 37(5):671-674. PubMed ID: 38626399
[TBL] [Abstract][Full Text] [Related]
7. Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice.
Shimizu M; Suemizu H; Mitsui M; Shibata N; Guengerich FP; Yamazaki H
Xenobiotica; 2017 Oct; 47(10):844-848. PubMed ID: 27852146
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of primary metabolites 5-hydroxythalidomide and 5'-hydroxythalidomide formed after oral administration of thalidomide in the rabbit, a thalidomide-sensitive species.
Kuwagata M; Hasegawa T; Takashima H; Shimizu M; Kitajima S; Yamazaki H
J Toxicol Sci; 2021; 46(12):553-560. PubMed ID: 34853241
[TBL] [Abstract][Full Text] [Related]
9. Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers.
Kamimura H; Ito S; Nozawa K; Nakamura S; Chijiwa H; Nagatsuka S; Kuronuma M; Ohnishi Y; Suemizu H; Ninomiya S
Drug Metab Dispos; 2015 Mar; 43(3):309-16. PubMed ID: 25504502
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.
Yamazaki H; Suemizu H; Kazuki Y; Oofusa K; Kuribayashi S; Shimizu M; Ninomiya S; Horie T; Shibata N; Guengerich FP
Chem Res Toxicol; 2016 Aug; 29(8):1279-81. PubMed ID: 27464947
[TBL] [Abstract][Full Text] [Related]
11. In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice.
Yamazaki H; Suemizu H; Murayama N; Utoh M; Shibata N; Nakamura M; Guengerich FP
Chem Res Toxicol; 2013 Mar; 26(3):486-9. PubMed ID: 23419139
[TBL] [Abstract][Full Text] [Related]
12. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes.
Uehara S; Yoneda N; Higuchi Y; Yamazaki H; Suemizu H
Drug Metab Dispos; 2020 Jul; 48(7):580-586. PubMed ID: 32357972
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.
Chowdhury G; Shibata N; Yamazaki H; Guengerich FP
Chem Res Toxicol; 2014 Jan; 27(1):147-56. PubMed ID: 24350712
[TBL] [Abstract][Full Text] [Related]
14. Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA.
Murayama N; Suemizu H; Uehara S; Kusama T; Mitsui M; Kamiya Y; Shimizu M; Guengerich FP; Yamazaki H
J Toxicol Sci; 2018; 43(6):369-375. PubMed ID: 29877213
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide metabolism by the CYP2C subfamily.
Ando Y; Fuse E; Figg WD
Clin Cancer Res; 2002 Jun; 8(6):1964-73. PubMed ID: 12060642
[TBL] [Abstract][Full Text] [Related]
16. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
Kosaka K; Hiraga N; Imamura M; Yoshimi S; Murakami E; Nakahara T; Honda Y; Ono A; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Aikata H; Ochi H; Ishida Y; Tateno C; Yoshizato K; Sasaki T; Chayama K
Biochem Biophys Res Commun; 2013 Nov; 441(1):230-5. PubMed ID: 24140055
[TBL] [Abstract][Full Text] [Related]
17. Formation of reactive metabolites of benzbromarone in humanized-liver mice.
Cho N; Suemizu H; Kamimura H; Ohe T; Ito F; Akita H; Kobayashi K
Drug Metab Pharmacokinet; 2022 Dec; 47():100467. PubMed ID: 36223709
[TBL] [Abstract][Full Text] [Related]
18. An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals.
Uehara S; Higuchi Y; Yoneda N; Kawai K; Yamamoto M; Kamimura H; Iida Y; Oshimura M; Kazuki Y; Yamazaki H; Hikita H; Takehara T; Suemizu H
Drug Metab Pharmacokinet; 2022 Feb; 42():100410. PubMed ID: 34839181
[TBL] [Abstract][Full Text] [Related]
19. Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity.
Murayama N; Kazuki Y; Satoh D; Arata K; Harada T; Shibata N; Guengerich FP; Yamazaki H
J Toxicol Sci; 2017; 42(3):343-348. PubMed ID: 28496040
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans.
Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM
J Pharmacol Exp Ther; 2004 Aug; 310(2):571-7. PubMed ID: 15075384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
